The development of SIRT5 inhibitors (for example, NRD167) now provides a tool to intentionally increase malonylation in tumors, and early results in both leukemia and solid tumors (such as lung cancer) are promising (Zou et al. 2023; Li And Melnick 2021). This evidence concerns the gene SIRT5 and lung cancer.